Cargando…

FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression

Fibroblast growth factor receptor 1 (FGFR1) is widely recognized as a key player in mammary carcinogenesis and associated with the prognosis and therapeutic response of breast cancers. With the aim of investigating the correlation between FGFR1 expression and estrogen receptor (ER) and exploring the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lv, Qing, Guan, Shiming, Zhu, Mingjie, Huang, Hu, Wu, Junqiang, Dai, Xiaofeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013883/ https://www.ncbi.nlm.nih.gov/pubmed/33783288 http://dx.doi.org/10.1177/15330338211004935

Ejemplares similares

FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ERα-Positive Breast Cancer Cells
por: Turczyk, Lukasz, et al.
Publicado: (2017)

Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer
por: Volpato, Milene, et al.
Publicado: (2020)

Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma
por: Ma, Ji, et al.
Publicado: (2014)

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
por: Esserman, Laura J, et al.
Publicado: (2005)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer
por: Kim, Yu Cheon, et al.
Publicado: (2021)

Dynamic surveillance of tamoxifen‐resistance in ER‐positive breast cancer by CAIX‐targeted ultrasound imaging
por: Li, Ying, et al.
Publicado: (2020)

Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer
por: Liu, Ying, et al.
Publicado: (2020)

Huaier extract synergizes with tamoxifen to induce autophagy and apoptosis in ER-positive breast cancer cells
por: Qi, Wenwen, et al.
Publicado: (2016)

Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer
por: Maselli, Angela, et al.
Publicado: (2019)

Checkpoint Kinase 2 Inhibition Can Reverse Tamoxifen Resistance in ER-Positive Breast Cancer
por: Tsoi, Ho, et al.
Publicado: (2022)

Modulation of transforming growth factor beta expression and induction of apoptosis by tamoxifen in ER positive and ER negative breast cancer cells.
por: Benson, J. R., et al.
Publicado: (1996)

The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer
por: Liu, Shu-Shu, et al.
Publicado: (2020)

A retrospective cohort study of tamoxifen versus surgical treatment for ER-positive gynecomastia
por: He, Weili, et al.
Publicado: (2023)

miR-221/222 sponge abrogates tamoxifen resistance in ER-positive breast cancer cells through restoring the expression of ERα
por: Ouyang, Yan Xiu, et al.
Publicado: (2021)

Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ
por: Mishra, Ameet K., et al.
Publicado: (2016)

Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer [Corrigendum]
Publicado: (2022)

COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR
por: Lu, Renquan, et al.
Publicado: (2016)

An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer
por: Zhou, Xin, et al.
Publicado: (2014)

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer
por: Zboril, Emily K., et al.
Publicado: (2023)

The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer
por: Law, Emily K., et al.
Publicado: (2016)

Although c-MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER-positive breast cancer
por: Chen, Rui, et al.
Publicado: (2020)

Hyperactivation of MAPK Induces Tamoxifen Resistance in SPRED2-Deficient ERα-Positive Breast Cancer
por: Vafeiadou, Vasiliki, et al.
Publicado: (2022)

CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance
por: Gao, Tian, et al.
Publicado: (2014)

Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer
por: Tsoi, Ho, et al.
Publicado: (2022)

Disruption of the ER-α36-EGFR/HER2 Positive Regulatory Loops Restores Tamoxifen Sensitivity in Tamoxifen Resistance Breast Cancer Cells
por: Yin, Li, et al.
Publicado: (2014)

ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid
por: Meligova, Aggeliki K., et al.
Publicado: (2023)

SRSF5 Regulates the Expression of BQ323636.1 to Modulate Tamoxifen Resistance in ER-Positive Breast Cancer
por: Tsoi, Ho, et al.
Publicado: (2023)

TNFα Enhances Tamoxifen Sensitivity through Dissociation of ERα-p53-NCOR1 Complexes in ERα-Positive Breast Cancer
por: Kim, Hyunhee, et al.
Publicado: (2021)

Tamoxifen induces hypercoagulation and alterations in ERα and ERβ dependent on breast cancer sub-phenotype ex vivo
por: Pather, K., et al.
Publicado: (2020)

LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer
por: Xue, Xingyang, et al.
Publicado: (2015)

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2021)

BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast
por: Millar, E K A, et al.
Publicado: (2009)

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen
por: Prat, A., et al.
Publicado: (2012)

Paeoniflorin Enhances the Sensitivity of ER-Positive Breast Cancer Cells to Tamoxifen through Promoting Sirtuin 4
por: Zhang, Pei, et al.
Publicado: (2022)

SIRT4 enhances the sensitivity of ER‐positive breast cancer to tamoxifen by inhibiting the IL‐6/STAT3 signal pathway
por: Xing, Jilin, et al.
Publicado: (2019)

The Utility of SOX2 and AGR2 Biomarkers as Early Predictors of Tamoxifen Resistance in ER-Positive Breast Cancer Patients
por: Zamzam, Yomna, et al.
Publicado: (2021)

Tamoxifen-Independent Recombination in the RIP-CreER Mouse
por: Liu, Yanmei, et al.
Publicado: (2010)

Effects of Jaeumkanghwa-tang on tamoxifen responsiveness in preclinical ER+ breast cancer model
por: De Oliveira Andrade, Fabia, et al.
Publicado: (2019)

ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer
por: Reese, Jordan M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_t29jdom3q79j905vtd1hek8v1c